Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.66 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 3/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116386 | 1.00 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL525862 | 1.00 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| Hydrochloric Acid SCHEMBL28350663 | 0.98 | CTSK (0.64) | CTSKCTSSATMGABRB1GABRB2 | |
| Bromide SCHEMBL8184293 | 0.98 | CTSK (0.64) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL15671568 | 0.94 | CTSK (0.67) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL15671569 | 0.94 | CTSK (0.67) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL3759870 | 0.91 | CTSK (0.56) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL27158950 | 0.91 | CTSK (0.56) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL16171655 | 0.90 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL16174111 | 0.90 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500361-B | Preparation method of (S) -4-phenyl-2-oxazolidinone | 甘肃瀚聚药业有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-114085201-A | Preparation method of chiral bicyclic gamma-butyrolactone compound | 山东第一医科大学(山东省医学科学院) | 2022-02-25 | — | — | CN | claimed |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-02-05 | — | — | US | claimed |
| EP-1984358-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | Chong Kun Dang Pharmaceutical Corp. (KR) | 2008-10-29 | — | — | EP | claimed |
| WO-2007091753-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2007-08-16 | — | — | WO | claimed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N.V. (DE) | 2025-12-25 | — | — | US | disclosed |
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-4172832-A | Mercaptoalcohols and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| EP-0004134-A1 | Beta-lactam antibacterial agents, their pharmaceutical compositions and process for their preparation | BEECHAM GROUP PLC (GB) | 1979-09-19 | — | — | EP | disclosed |
| US-4112086-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4108992-A | BACTERICIDES | BEECHAM GROUP LIMITED (GB) | 1978-08-22 | — | — | US | disclosed |
| US-4101656-A | 7β-Acylamino-3-(alkanesulfonamidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them | SMITHKLINE CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3968226-A | 3-Heterocyclic thiomethylcephalosporins as antibacterial agents | SMITHKLINE CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | BMP1, BMPR1A, BMPR1B | CTSK 319/4885CTSS 254/4885ATM 4630/4885 |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | SRR, NPEPPS, DNPEP | CTSK 2431/4885CTSS 898/4885ATM 4636/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | CTSK 2406/4885CTSS 1555/4885ATM 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.